Altex-Alternatives to Animal Experimentation

Papers
(The TQCC of Altex-Alternatives to Animal Experimentation is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Alternative Methods in Science: Towards Fluidic Systems60
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay_suppl134
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl528
Sensitivity analysis and quality indicators for an in vitro oral irritation assay19
Validation of an Endopep-suspension immunoassay for the diagnostics of human botulism_suppl18
Animal research ethics as interaction of research ethics, animal ethics, and (animal protection) law17
The effect of surfactants and film-forming polymers on pulmonary surfactant function measured in vitro is dose rate dependent_suppl14
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency13
Off to a good start? Review of the predictivity of reactivity methods modelling the molecular initiating event of skin sensitization11
Intestinal in vitro transport assay combined with physiologically based kinetic modeling as a tool to predict bile acid levels in vivo_suppl111
Predicting Acute Oral Toxicity Using AcutoX: An Animal Product-Free and Metabolically Relevant Human Cell-Based Test10
REACH out-numbered! The future of REACH and animal numbers10
A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A10
Developmental neurotoxicity (DNT): A call for implementation of new approach methodologies for regulatory purposes: Summary of the 5th International Conference on DNT Testing9
Chemical selection for the Thyroid Validation Study coordinated by EURL ECVAM and involving EU-NETVAL laboratories_suppl19
Mapping out strategies to further develop human-relevant, new approach methodology (NAM)-based developmental neurotoxicity (DNT) testing9
The long way from raw data to NAM-based information: Overview on data layers and processing steps9
Beyond Animal Testing Index: Benchmarking tool for a world beyond animal testing_suppl49
Validation study for the evaluation of MCTT HCE™ test method for eye safety assessment of medical devices8
Stakeholder input towards further refinement and consolidation of the alternative safety profiling algorithm (ASPA) for next generation risk assessment (NGRA)_suppl28
E-validation – Unleashing AI for validation7
Developing a global education hub for animal-free innovation_suppl7
Making safety decisions for a sunscreen active ingredient using next-generation risk assessment: Benzophenone-4 case study7
Chemical fate in vitro: A physiological biokinetic (PBK) model for cell-based assays_suppl36
Exploring the synergy of CRISPR and microphysiological systems6
Protectiveness of NAM-based hazard assessment – which testing scope is required?_suppl16
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations6
Chemical selection for the Thyroid Validation Study coordinated by EURL ECVAM and involving EU-NETVAL laboratories_suppl36
Mapping physiology: A systems biology approach for the development of alternative methods in toxicology6
Non-animal approaches – Concept, validation, and regulatory acceptance: The fourth Asian Congress of Alternatives to Animal Experiments (4ACAAE) and the seventh Annual Meeting of the Society for Alter6
3Rs: Progress or a fig leaf?5
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl65
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl25
Lost in NAMs-lation: A review of animal-free science definitions5
ALTEX Proceedings TIERethik Corrigendum to Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment4
Low rejection rate for animal experiments in Germany despite legal reform4
The Virtual Human Platform for Safety Assessment (VHP4Safety) project: Next generation chemical safety assessment based on human data4
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay_suppl34
Role of standards and funding in accelerating the development and use of microphysiological systems4
AOP 460: Antagonism of Smoothened receptor leading to orofacial clefting_suppl14
In vitro-based prediction of human plasma concentrations of food-related compounds_suppl14
Women in Alternatives4
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay4
Chemical fate in vitro: A physiological biokinetic (PBK) model for cell-based assays_suppl24
The Alarming Consequences of Workforce Reductions at the FDA, EPA, NIH and CDC in the United States4
Investigation of the publication rate of recent research projects using non-human primates in France4
From cellular perturbation to probabilistic risk assessments3
INFOGUT – International Networking on In Vitro Colon Models Simulating Gut Microbiota-Mediated Interactions – 1st Annual Meeting3
Transition to animal-free science: Phasing out animal experiments, phasing in innovation3
Comparative evaluation of rat and human in vitro assays for evaluation of thyroid toxicity_suppl13
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations_suppl63
Assessment of developmental neurotoxicology-associated alterations in neuronal architecture and function using Caenorhabditis elegans_suppl3
A path forward advancing microphysiological systems3
Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment3
Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis_suppl13
Building confidence in PBK model predictions in the absence of human kinetic data: Benzophenone-4 case study_suppl13
Second scientific sessions and international conference of the Society for Alternatives to Animal Testing in Sri Lanka (SAAT-SL)3
Material-mediated pyrogens in medical devices: Myth or reality?_suppl23
Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways3
Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals_suppl13
Human relevant frontiers in drug safety and efficacy3
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations_suppl73
AOP 460: Antagonism of Smoothened receptor leading to orofacial clefting2
A human iPSC-based in vitro neural network formation assay to investigate neurodevelopmental toxicity of pesticides_suppl22
The need for epigenotoxicity testing2
The SCAHT Adverse Outcome Pathway (AOP)_HUB: A hands-on platform for information exchange, sharing, and developing AOPs2
Qualitative and quantitative concentration-response modelling of gene co-expression networks to unlock hepatotoxic mechanisms for next generation chemical safety assessment2
Advancing humane and human-relevant science: The 8th Annual Conference of the Society for Alternatives to Animal Experiments – India (SAAE-I 2025)2
Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals_suppl22
Bridging the gap in chemical risk assessment: Leveraging metabolite similarity for enhanced read-across applications2
Micro-replace systems2
Alternative methods, new approach methodologies (NAMs) and artificial intelligence (AI): Approaching the future of science2
Phasing in human-relevant science: Why the UK’s roadmap matters – and how to make it work2
Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare2
Phase-out planning for animal experimentation: A definition, an argument, and seven action points1
Guidance for Good In Vitro Reporting Standards (GIVReSt) – A draft for stakeholder discussion and background documentation1
Impact of gut permeability on estimation of oral bioavailability for chemicals in commerce and the environment1
Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis1
Chemical fate in vitro: A physiological biokinetic (PBK) model for cell-based assays_suppl41
Review on organ-on-chips for medicines safety assessment: A European regulatory perspective_suppl11
Multiparametric evaluation of different FBS-free replacement media for widely used human cancer cell lines1
Building confidence in PBK model predictions in the absence of human kinetic data: Benzophenone-4 case study1
Advancing skin sensitization potency categorization using U-SENS™ in OECD TG 4971
A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A_suppl1
The benefits of validation of methods for toxicity testing outweigh its costs1
Fish Count, Too – The Animal Toll of REACH Aquatic Toxicity Tests_suppl21
Integrated skin sensitization assessment based on OECD methods (III): Adding human data to the assessment_suppl31
School of Animal Welfare and Ethics (SAWE) – 1st Edition1
Ways to broaden the awareness, consideration and adoption of new approach methodologies (NAMs)1
Chemical fate in vitro: A physiological biokinetic (PBK) model for cell-based assays _suppl11
3 Days for 3Rs 2023: Refinement, reduction, replacement1
Towards NAM-based risk assessment for developmental neurotoxic effects, illustrated with chlorpyrifos1
Material-mediated pyrogens in medical devices: Myth or reality?_suppl11
International conference and workshop on “New Approach Methodologies (NAMs) in Pharmacology and Toxicology”1
Virtual control groups in non-clinical toxicology – A replicability challenge1
Integrated skin sensitization assessment based on OECD methods (III): Adding human data to the assessment_suppl21
The turning point: April 2025 marks historic shift in US animal testing policy1
The impact of biostatistics on hazard characterization using in vitro developmental neurotoxicity assays1
Integrated skin sensitization assessment based on OECD methods (III): Adding human data to the assessment_suppl11
0.24313902854919